Photodynamic Therapy with Verteporfin in Recurrent Choroidal Neovascularization following Argon-laser Coagulation
Gabel A., Wachtlin J., Wehner A., Heimann H., Foerster M. H.
Augenklinik, Klinikum Benjamin Franklin, FU Berlin
Purpose: Photodynamic therapy (PDT) with Verteporfin has succesfully been introduced for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in age related macular degeneration (AMD). However, it is unclear, wether patients with recurrent CNV after argon lasercoagulation profit from PDT to the same degree.
Method: Retrospectivly, we have analysed the development of visual acuity after standard PDT treament in patients with recurrent CNV after laser coagulation for CNV in AMD or due to myopia or postinflammatory scars. At each control we assessed the ETDRS visual acuity and performed a fluorescein angiogram.
Results: In total we analysed the data of 20 eyes of 19 patients with AMD. All eyes had a follow-up of at least 12 months, nine eyes were followed for more than two years (maximum 34,5 months). Mean initial visual acuity was 20/100 (200/500 to 20/40). At the 12 months examination 15 of 20 eyes (75 %) had only a moderate visual loss of less than three lines. After 24 months, 9 eyes (55,6 %) had lost less than 3 lines. All seven eyes with recurrent CNV after laser coagulation for CNV with myopia or postinflammatory scars had a mean follow up of 17 months (maximum 31,5 months). The mean initial visual acuity was 20/50. After 12 months of follow-up five of seven eyes (71,4 %) had lost less than 3 lines.
Zurück | Back